For an adult with advanced non‑small cell lung cancer and no prior EGFR‑TKI exposure, which EGFR inhibitor should be selected based on the specific EGFR mutation (e.g., exon 19 deletion, L858R, T790M, or uncommon mutations such as G719X, L861Q, S768I)?

Selection of EGFR Inhibitor Based on Gene Mutation

For advanced NSCLC with EGFR exon 19 deletion or L858R mutation, osimertinib is the definitive first-line choice; for uncommon mutations (G719X, L861Q, S768I), afatinib is preferred with osimertinib as an alternative; for exon 20 insertions, platinum-based chemotherapy followed by amivantamab or mobocertinib after progression is the standard approach; T790M mutations arising after first/second-generation TKI failure should be treated with osimertinib. 1, 2

Common Sensitizing Mutations (Exon 19 Deletion and L858R)

Osimertinib 80 mg daily is the gold standard first-line therapy for patients with exon 19 deletions or L858R mutations 1, 2. This third-generation TKI demonstrates superior efficacy compared to earlier generation agents and has become the preferred option across all major guidelines (ASCO, NCCN, ESMO) 3, 4, 1.

Alternative Options for Common Mutations:

• Combination therapy with osimertinib plus platinum doublet chemotherapy or amivantamab plus lazertinib may be considered for select high-risk patients, though this represents a weak recommendation 2
• Second-generation TKIs (afatinib, dacomitinib) are acceptable alternatives when osimertinib is unavailable, though they carry greater toxicity 5
• First-generation TKIs (gefitinib, erlotinib, icotinib) remain options in resource-limited settings but are inferior to osimertinib 6, 5

Critical Caveat:

Single-agent immune checkpoint inhibitors should NOT be offered to any patient with activating EGFR mutations, regardless of PD-L1 expression 1, 2. This is a strong recommendation based on exclusion of EGFR-mutant patients from pivotal immunotherapy trials and lack of demonstrated benefit 3.

Uncommon Sensitizing Mutations (G719X, L861Q, S768I)

Afatinib is the only FDA-approved agent for these uncommon mutations and should be the first choice 3. The approval was based on pooled data from LUX-Lung 2,3, and 6 trials showing that PFS and response rates with afatinib 40 mg daily were similar to outcomes in patients with common mutations 3.

Mutation-Specific Considerations:

For L861Q specifically: Osimertinib may be preferred over afatinib based on retrospective data suggesting superior response rates (78% vs 56.3%) and longer median PFS (15.2 months) 4. This "classical-like" mutation appears to behave more similarly to exon 19 deletions and L858R 7.

For G719X: Afatinib shows strong activity (77.8% response rate) and should remain first choice 4. Osimertinib achieved 53% response rate with median PFS of 8.2 months in this subgroup 4.

For S768I: Both agents show activity, with afatinib achieving 100% response rate in small cohorts 4. Osimertinib showed 38% response rate with median PFS of 12.3 months 4.

Treatment Algorithm for Uncommon Mutations:

1. First choice: Afatinib (strong recommendation, FDA-approved) 1, 2
2. Alternative: Osimertinib (weak recommendation, particularly for L861Q) 1, 2
3. If TKI evidence is limited: Platinum-based chemotherapy with pemetrexed may be considered 3

Important: The NCCN and ASCO guidelines both recommend afatinib or osimertinib as preferred options, with the choice tailored to the specific mutation identified 4, 1, 2.

EGFR Exon 20 Insertions

These mutations are fundamentally different and resistant to standard EGFR TKIs 3. The structural disruption at the α-C helix lowers affinity for conventional TKIs to levels similar to wild-type EGFR 3.

Treatment Approach:

1. First-line: Platinum-based chemotherapy (preferably without checkpoint inhibitors due to potential toxicity with later targeted therapy) 3
2. After chemotherapy progression: Amivantamab (bispecific EGFR/MET antibody) or mobocertinib (selective oral TKI) 3

Updated recommendation: Amivantamab plus carboplatin-pemetrexed chemotherapy is now recommended as first-line therapy based on significant PFS improvement (HR 0.40, P<0.001) and higher response rates (73% vs 47%) compared to chemotherapy alone 5. This represents a strong ASCO recommendation 1, 2.

Key Safety Considerations:

Amivantamab-specific adverse events include paronychia, rash, peripheral edema, and infusion reactions 5. These are generally manageable but require monitoring.

T790M Resistance Mutation

Osimertinib is the definitive treatment for T790M-mediated resistance after progression on first- or second-generation EGFR TKIs 6. This third-generation TKI was specifically designed to overcome T790M resistance and is FDA-approved for this indication 6.

Clinical Context:

• T790M accounts for approximately 50-60% of acquired resistance to first/second-generation TKIs
• Re-biopsy or liquid biopsy (ctDNA) is essential to document T790M before switching therapy
• If T790M is present at baseline (rare), osimertinib should be used from the start

Compound and Concurrent Mutations

When multiple targetable alterations coexist, comprehensive NGS analysis is mandatory to identify the dominant clone 3. In confirmed co-presence of different alterations, platinum-based chemotherapy with or without TKIs should be prioritized 3.

Important Principle:

While EGFR mutations and other major oncogenic drivers (ALK, ROS1, RAS, MET) are generally mutually exclusive, co-occurring alterations can impact response to targeted therapies 3. Outcomes with EGFR TKIs in this setting are generally inferior to single-alteration cases 3.

Common Pitfalls to Avoid

1. Do not use immunotherapy alone in any EGFR-mutant patient, regardless of PD-L1 status 1, 2
2. Do not assume all EGFR mutations respond equally to the same TKI—mutation-specific selection is critical 3, 4
3. Do not treat exon 20 insertions with standard EGFR TKIs—they require chemotherapy or specialized agents 3
4. Do not skip comprehensive molecular testing—knowing the exact mutation subtype determines optimal therapy 3, 4
5. Do not use gefitinib for uncommon mutations—PFS is significantly shorter compared to afatinib 3

Regional Considerations

In China, additional approved agents include almonertinib (aumolertinib), furmonertinib (alflutinib), and icotinib for various EGFR-mutant indications 6, 5. These third-generation agents show comparable efficacy to osimertinib in Asian populations but are not globally available.